- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.11. | RenovoRx, Inc.: RenovoRx CEO Shaun Bagai to Present at the Alliance Global Partners Emerging AgBiotech/Bio-Solutions Virtual Showcase on November 20th | 1 | GlobeNewswire (USA) | ||
| 13.11. | RenovoRx, Inc.: RenovoRx Reports Third Quarter 2025 Financial Results, Including Approximately $900,000 in Year-to-Date Revenue, and Provides Business Update | 160 | GlobeNewswire (Europe) | September 30, 2025 Cash and Cash Equivalents at $10 million Revenue Expected to Grow in 2026 and Continue to Offset Cash Burn Management to Host Conference Call Today at 4:30 p.m. ET MOUNTAIN VIEW... ► Artikel lesen | |
| 13.11. | RenovoRx, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 13.11. | RenovoRx, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 06.11. | UCLA oncology surgeon joins RenovoRx's scientific advisory board | 1 | Investing.com | ||
| 06.11. | RenovoRx, Inc.: RenovoRx Strengthens Scientific Advisory Board (SAB) with Pancreatic Cancer Expert Timothy Donahue, MD | 1 | GlobeNewswire (USA) | ||
| RENOVORX Aktie jetzt für 0€ handeln | |||||
| 04.11. | RenovoRx, Inc.: RenovoRx CEO Shaun Bagai to Participate at the Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum on November 20th | 1 | GlobeNewswire (USA) | ||
| 09.10. | RenovoRx adds interventional oncology expert to scientific advisory board | 2 | Investing.com | ||
| 09.10. | RenovoRx, Inc.: RenovoRx Expands Scientific Advisory Board with Internationally Renowned Interventional Oncologist, Thierry de Baère, MD, PhD | 1 | GlobeNewswire (USA) | ||
| 26.09. | RenovoRx reports first patient procedure with RenovoCath | 1 | MassDevice | ||
| 25.09. | First registry-eligible patient procedure completed in RenovoRx's study | 1 | Investing.com | ||
| 25.09. | RenovoRx, Inc.: RenovoRx's PanTheR Post-Marketing Registry Study Progresses with First Clinical Procedure and Addition of Two Participating Clinical Sites | 1 | GlobeNewswire (USA) | ||
| 14.08. | RenovoRx: EPS übertrifft Schätzungen - Umsatz schlechter als erwartet | 13 | Investing.com Deutsch | ||
| 14.08. | RenovoRx, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 14.08. | RenovoRx GAAP EPS of -$0.08 beats by $0.01, revenue of $0.04M misses by $0.21M | 3 | Seeking Alpha | ||
| 06.08. | RenovoRx expands commercial footprint to 13 cancer centers | 1 | Investing.com | ||
| 06.08. | RenovoRx, Inc.: RenovoRx Expands U.S. Commercialization Efforts for the RenovoCath Device with Growing Customer Demand and Key Leadership Hire | 111 | GlobeNewswire (Europe) | RenovoRx increases its commercial footprint to thirteen leading National Cancer Institute-designated and community centers approved to purchase RenovoCath Four active cancer center customers are... ► Artikel lesen | |
| 28.07. | RenovoRx startet Post-Marketing-Studie für Krebstherapie-System | 2 | Investing.com Deutsch | ||
| 28.07. | RenovoRx to launch post-marketing registry study for cancer device | 1 | Investing.com | ||
| 27.06. | RenovoRx, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings |
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 78,60 | +0,13 % | Alarm bei Evotec! BioNTech und Vidac Pharma mit Erfolgen beim Kampf gegen Krebs! Analysten raten zum Kauf! | Bei Evotec läuten die Alarmglocken. Ein Großaktionär ist komplett beim deutschen Biotech-Unternehmen ausgestiegen. Dabei notiert das Wertpapier auf dem Niveau von 2016. Einen Meilenstein hat dagegen... ► Artikel lesen | |
| CUREVAC | 4,056 | -0,93 % | Morgen-Update: Curevac sorgt für Spannung - kommt bald die Entscheidung? | ||
| MODERNA | 25,415 | -0,10 % | Moderna, Inc.: EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's mNEXSPIKE | mNEXSPIKE is Moderna's third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine, mRNA) and mRESVIA (Respiratory Syncytial Virus Vaccine)mNEXSPIKE will be available in the... ► Artikel lesen | |
| BIOGEN | 144,70 | -0,86 % | Lululemon, Biogen to exit Nasdaq 100 with Alnylam, Seagate among additions | ||
| ILLUMINA | 111,64 | -0,29 % | MyOme, Inc: Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme's Clinical Trial That Could Save U.S. Healthcare $200 Billion Annually | Partnership unites Illumina's leading sequencing technology with cutting-edge clinical genomics analyses and AI to advance precision medicine for early detection and prevention. SAN DIEGO... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 48,200 | +1,26 % | CRISPR Therapeutics AG: CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310 Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering | -Data presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions 2025- -Phase 1 clinical data for CTX310® demonstrate robust, dose-dependent reductions in... ► Artikel lesen | |
| VIKING THERAPEUTICS | 30,460 | +0,21 % | 1 Bold Prediction for Viking Therapeutics in 2026 | ||
| ATAI BECKLEY | 3,544 | -1,69 % | Psychedelika bewegen sich über das Versprechen hinaus - Atai und Bioxyne im Rampenlicht | ||
| TWIST BIOSCIENCE | 26,420 | -0,26 % | Aptamer Group signs licensing deal with Twist Bioscience for NGS market | ||
| BIOXCEL THERAPEUTICS | 1,576 | -1,87 % | BioXcel Therapeutics, Inc. - 8-K, Current Report | ||
| BRIACELL THERAPEUTICS | 7,550 | +1,34 % | BriaCell Therapeutics Corp.: BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS 2025 | BriaCell presents positive clinical data in three posters at the San Antonio Breast Cancer Symposium (SABCS- - Phase 3 study of Bria-IMT plus immune check point inhibitor (CPI) continues to support... ► Artikel lesen | |
| VISTAGEN THERAPEUTICS | 4,360 | -0,68 % | Vistagen Therapeutics, Inc. - 8-K, Current Report | ||
| QIAGEN | 37,990 | -0,90 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| NURIX THERAPEUTICS | 18,840 | -0,89 % | Cathie Wood's ARK sells Iridium stock, buys Nurix on Wednesday | ||
| EDGEWISE THERAPEUTICS | 22,770 | 0,00 % | Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules | BOULDER, Colo., Dec. 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical... ► Artikel lesen |
RENOVORX INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,101 (-10,70 %) liegt der Kurs bei 0,840 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RENOVORX INC finden Sie auf Wallstreet Online.